Trial Profile

A clinical trial in China of lanifibranor in MASH (metabolic dysfunction-associated steatohepatitis)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lanifibranor (Primary)
Indications Non-alcoholic steatohepatitis
Focus Therapeutic Use

Most Recent Events

14 Feb 2025 New trial record
10 Feb 2025 According to Inventiva pharma media release, IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in MASH, and the randomization of the first patient.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com